In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
The Grand Debate 2: ICD – Myocardial revascularisation: STICH (Surgical Treatment for Ischemic Heart Failure)
Session

Event : Heart Failure 2017

Topic : Chronic Heart Failure – Treatment

  • Session type : Debate Session
  • Date : 01 May 2017
  • Time : 16:30 - 18:00

6 presentations in this session

Surgery beats optimal medical therapy in ischaemic heart failure - Introduction.

Event : Heart Failure 2017

  • Session : STICH (Surgical Treatment for Ischemic Heart Failure)
  • Speaker : K Swedberg (Goteborg,SE)

Surgical revascularisation beats optimal medical therapy in ischaemic heart failure - PRO.

Event : Heart Failure 2017

  • Session : STICH (Surgical Treatment for Ischemic Heart Failure)
  • Speaker : E Velazquez (New Haven,US)

Surgical revascularisation beats optimal medical therapy in ischaemic heart failure - CONTRA.

Event : Heart Failure 2017

  • Session : STICH (Surgical Treatment for Ischemic Heart Failure)
  • Speaker : D Perera (London,GB)

Rebuttal - PRO.

Event : Heart Failure 2017

  • Session : STICH (Surgical Treatment for Ischemic Heart Failure)

Rebuttal - CONTRA.

Event : Heart Failure 2017

  • Session : STICH (Surgical Treatment for Ischemic Heart Failure)

Grand finale.

Event : Heart Failure 2017

  • Session : STICH (Surgical Treatment for Ischemic Heart Failure)
  • Speaker : K Swedberg (Goteborg,SE)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are